Population Health takes center stage (PRVR 8/18 – 22/2014)

This week on Pharma Research VIDEO Report: 1) A pilot project shows mobile might be the most cost-effective way of reaching Medicaid recipients. 2) PMLive.com wonders about wearable tech’s continued consumer use. 3) The FDA is concerned about the effects of publishing early clinical drug test data. 4) A study shows the existence of four digital health consumer segments. 5) Dr. David Nash of the Jefferson School of Population health speaks with PRVR about Population Health, a specialty area exclusive to Thomas Jefferson University.

Preventing MD shortages; Getting “Well-Being” in control (PRVR 8/11/14)

This week on Pharma Research VIDEO Report: 1) FutureDocs Forecasting tool looks to help discover the causes of a projected MD shortage. 2) Gallup-Healthways Well-Being 5™ measures, reports and tracks the strongest predictor of health and performance outcomes over time and well-being. 3) PWC expects healthcare insurance pricing won’t increase as much in 2015 as in pre-Obamacare years.  4) Dr Social CEO Claudio Teri claims that the success of TripAdvisor portends solid consumer participation in his physician review service.

Google’s impressive HC exploits; Med device cos’ new biz model (PRVR 8/4/14)

This week on Pharma Research VIDEO Report:
1) Google’s Baseline Study is looking to create the fullest picture of a healthy human being, through data collection from personal trackers, health-related apps and a broad array of other essential data. The goal is to develop solutions to killer diseases. 2) 23andMe’s achieves a second life through $1.4 million NIH research grant. 3) Veronica Combs explains how healthcare reform and other factors are making medical device cos’ operating model obsolete. 4) The healthcare analytics market will achieve 25% compound annual growth rate through 2019.

CER low impact; Big Data In-patient MR; FDA continuing Mini-Sentinel? (PRVR–7/28-31/2014)

This week on Pharma Research VIDEO Report:
1) Experts agree the promise of comparative effectiveness research is having very little impact on healthcare decision making. 2) Dr. David Bates researched Big Data algorithms that he says can positively impact the expenditures on low-hanging fruit with in-patients. 3) The FDA must make a decision on whether or not to continue Mini-Sentinel, a program that queries 18 health plan and insurance partners about patient records that can show adverse events.

Apple iWatch’s HC info partners; HelloMD reworks MD-patient choices (PRVR–7-21-25/2014)

This week on Pharma Research VIDEO Report: 1) Apple’s iWatch — rumored to launch as early as October — with management team in place, and making impressive health care information partnerships.    2) Health startup HelloMD is recruiting top 1% of doctors and making them available to consumers who want to see the best and who are willing to pay cash for access.

Blackberry pursues health care; Google Glass: a Big Surgeon Solution? (PRVR–7/14-18/2014)

This week on Pharma Research VIDEO Report:  1) Blackberry tries out information solutions in health care to revive the business’ fortunes. Testing is underway in India.  2) The largest hospital group in the Carolinas is purchasing data to get a handle on two million patients’ lifestyle buying behavior.  3) A beta testing group, Glass Explorers, says surgeons will be making important use of Google Glass.  4) Best Practices LLC’s Chairman Chris Bogan discusses whether pharmaceutical company market research departments are sitting pretty with all the new information needs of senior managements.

MDs push mobile clinical apps; clinical apps to explode; Chris Bogan on Payer MR (PRVR–7/07/14)

This week on Pharma Research VIDEO Report: 1) Physicians have taken the next step with mobile health care devices, employing wearable tech to attempt to track patient progress and motivate activity. 2) Lux Research predicts a spike in clinical monitoring apps in the next 10 years that will make current personal mobile health care apps secondary in importance. 3) Best Practices LLC President & CEO Chris Bogan discusses his report, “Increasing Market Access Through Innovative Payer Market Research,” with a close look at why this research has become all consuming for pharmaceutical companies.

IMS buys part of Cegedim; Health policy researcher eschew social media (PRVR–6/30 to 7/3/2014)

This week on Pharma Research VIDEO Report:  1) IMS Health’s acquisition of assets of Cegedim vastly increases IMS’ size and may lead to new insights  2) New pharmaceutical research registry announcements.  3) Johnson & Johnson announces new alliances to explore early-stage therapeutic innovations for pharma, medical devices,diagnostics and consumer health.  4) Perelman School of Medicine reveals health policy researchers limit their social media use to communicate research findings  5) IDC Health Insights releases a new report to help payers effectively reach & engage segments of their member populations, which have changed due to ACA.

Here comes Google Fit. FDA’s disappointing social media guidance (PRVR–6/ 23/2014)

This week on Pharma Research VIDEO Report:  1) The healthcare app industry is set to explode with the entry of Google Fit, HealthKit and Android Wear. (Read Seeking Alpha’s summary of the situation: http://seekingalpha.com/article/2277433-with-google-fit-google-declares-war-with-apple-in-mobile-healthcare?uprof=45&dr=1)   2) Attorney John Osborn, writing for Forbes.com, comments regarding the FDA’s lack of guidance for companies and their social media interactions. 3) Toluna Regional VP Bob Leitman shares his thoughts on current pharmaceutical company market trends.

MDs subvert patient empowerment? Pharmacos need to obsess re patients (PRVR–6/16/2014)

This week on Pharma Research VIDEO Report:  1) Patients explain why empowerment is so important to them and impediments from doctors.  2) Wolff Olins declares why pharma companies must change their emphasis to patients and relationships with them.  3) For the fifth year in a row, the Epocrates medical reference app is tops for physicians on smartphones and tablets.  4) A former Merck analyst alleges in a whistleblower lawsuit that a 2009 market research study was mostly about selling more diabetes drugs to in HEB stores and to those covered by Blue Cross Blue Shield of Texas.


Get every new post delivered to your Inbox.

Join 1,128 other followers